ALIPAY+
19.9.2023 09:25:36 CEST | Business Wire | Press release
Ant Group officially welcomes seven new leading e-wallets and payment apps from Asia to the “Alipay+-in-China” Program (A+China Program). Users of mPay (Macao SAR, China), Hipay (Mongolia), Changi Pay (Singapore), OCBC (Singapore), Naver Pay (South Korea), Toss Pay (South Korea) and TrueMoney (Thailand) will be able to use their familiar home e-wallet on their own phone to enjoy seamless mobile payment experience in the Chinese mainland across Alipay’s vast merchant network.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230918947937/en/
(Photo: Business Wire)
The new additions bring the total number of overseas e-wallets accepted in the Chinese mainland to 10. AlipayHK (Hong Kong SAR, China), Touch ’n Go eWallet (Malaysia) and Kakao Pay (South Korea) piloted the Program in late 2022. In total, these payment methods reach a population of over 175 million in Southeast and East Asia.
Users of these e-wallets may use their own payment app wherever Alipay works, to enjoy secure, smooth and cashless payment, and transparent and competitive exchange rates. They can also enjoy additional promotional deals via Alipay+ Rewards, a digital cross-border marketing hub integrated into select wallet apps. The wallets’ teams are also providing familiar customer support to their roaming users, backed by Alipay+’s smart payment tech capabilities.
With the A+China Program, Alipay+ also officially welcomes five new mobile payment partners, including Hipay, Changi Pay, OCBC, Naver Pay and Toss Pay to its global merchant network.
A suite of cross-border mobile payment, marketing and digitalization solutions developed by the International Business Group of Ant Group, Alipay+ enables payment partners to connect global and local merchants to cross-border digital consumers.
Outside of China, Alipay+ covers 5 million merchants in 56 markets, and works with over 20 mobile payment partners across Asia which together serve over 1.4 billion consumer accounts. The A+China Program now extends Alipay+ service to tap into the massive merchant network of China with tens of millions of points of sales (POS).
The A+China Program is made possible by the guidance of the People’s Bank of China and support from NetsUnion Clearing Corporation, e-wallet partners, international card organizations as well as other partner financial institutions in China. Travelers may also choose to bind their international bank cards to an updated international version of Alipay to enjoy mobile payment and digital life services while in China.
Ant Group is rolling out extensive merchants’ education and marketing campaigns across the Chinese mainland, especially in the top tourist cities, to welcome Asian athletes, fans and travelers.
Douglas Feagin, Senior Vice President of Ant Group and Head of Alipay+ Cross-Border Mobile Payment Services, said expanding partners and merchant network, and enhancing digital operational capabilities of SMEs are key to Alipay+’s future strategy.
“A growing variety of mobile payment providers are joining this ecosystem of cross-border digital commerce, from mobile wallets, to banking apps, independent merchant apps and super-apps. We will invest faster and deeper in payment and digital marketing technologies to help our partners and merchants achieve robust, omni-channel growth,” said Feagin.
“As the chartered clearing institution of the People's Bank of China, NetsUnion Clearing Corporation provides secure and efficient transaction information interchange and fund clearing services for cross-border mobile payments of Ant Group and overseas digital wallets. We are committed to providing robust support for important cross-border mobile payment scenarios and events such as the Hangzhou Asian Games, to help nurture an open and inclusive cross-border consumption environment in China, and promote high-quality dual circulation of domestic and global economic cycles,” said the NetsUnion Clearing Corporation of China.
“We are deeply grateful for the guidance of the People’s Bank of China, the support of the NetsUnion Clearing Corporation, and the assistance from financial institutions and major international card organizations, for helping bring the world’s mobile wallet users and overseas bank card users to China as the Official Payment Partner of the Asian Games,” said Eric Jing, Chairman and CEO of Ant Group. “It is incredibly inspiring to see such regional multi-party partnership help travelers enjoy greater choice and convenience, and small businesses thrive in cross-border commerce with unprecedented innovations. We look forward to building wider and deeper collaboration to fulfill our shared mission to make the world a better place with the power of digital technologies.”
The total number of payments made in China through the pilot A+China wallets – Kakao Pay, Touch ’n Go eWallet and AlipayHK – grew 47 times in six months between March and August 2023. Shanghai, Guangzhou and Shenzhen are the favorite cities for travelers from South Korea, Malaysia and Hong Kong SAR. Food and beverage, retail and transportation are the three most common scenarios for these transactions.
According to PricewaterhouseCoopers1, by 2030 the number of cashless transactions will be about double to triple. While China leads the region in digital wallet usage, the rest of Asia, especially Southeast Asia, has become the world's fastest growing mobile payment market. FIS research2 shows that between 2018 and 2023 digital wallets in the region (excluding China) more than doubled their share of e-commerce transaction value and share of payment transaction value at point-of-sales grow six folds.
About Ant Group
Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
About Alipay+
Alipay+ is a suite of cross-border digital payment, marketing and digitalization solutions that help connect global merchants to consumers. Consumers enjoy seamless payment and a broad choice of deals using their preferred payment methods while travelling abroad. Small and medium-sized businesses may use Alipay+ digital tools to enhance efficiency and achieve omni-channel growth.
2 https://www.fisglobal.com/en/global-payments-report
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230918947937/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom